Zoetis Inc. (NYSE:ZTS) Shares Sold by McKinley Carter Wealth Services Inc.

McKinley Carter Wealth Services Inc. cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,003 shares of the company’s stock after selling 65 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Zoetis were worth $391,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of the company. Nomura Holdings Inc. acquired a new position in shares of Zoetis in the 4th quarter worth $1,825,000. NBC Securities Inc. grew its holdings in shares of Zoetis by 12.7% in the 1st quarter. NBC Securities Inc. now owns 7,414 shares of the company’s stock worth $1,254,000 after acquiring an additional 838 shares during the last quarter. Czech National Bank grew its holdings in shares of Zoetis by 0.4% in the 1st quarter. Czech National Bank now owns 80,781 shares of the company’s stock worth $13,669,000 after acquiring an additional 357 shares during the last quarter. BTC Capital Management Inc. acquired a new position in shares of Zoetis in the 1st quarter worth $6,896,000. Finally, PFW Advisors LLC acquired a new position in shares of Zoetis in the 1st quarter worth $1,845,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on ZTS shares. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Finally, BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Zoetis has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Price Performance

ZTS opened at $194.45 on Thursday. The stock has a market cap of $88.10 billion, a price-to-earnings ratio of 38.05, a PEG ratio of 2.99 and a beta of 0.89. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a fifty day moving average price of $188.76 and a 200 day moving average price of $176.70.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.41 earnings per share. Analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.89%. Zoetis’s dividend payout ratio is currently 33.86%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.